High caffeine levels associated with weight loss and type 2 diabetes risk: BMJ

Published Date: 17 Mar 2023

UK: A recent study published in BMJ Medicine found that more caffeine in the blood can reduce the risk of type 2 diabetes and obesity. more...

Read Full News

Latest News

Insulin Timing Can Be Flexible in CF-Related Diabetes

In adults with cystic fibrosis–related diabetes, insulin given after meals provides glucose control similar to that with standard mealtime dosing, offering a flexible treatment option.

Inactivity, Not Diet, Tops AI Obesity Predictors

Physical inactivity is the single strongest predictor of obesity across US counties, according to a new AI-driven analysis explaining 78% of the variation in county-level obesity prevalence.

GLP-1s and Mental Health: What's Safe to Say to Patients?

New evidence shows GLP-1s are safe and potentially life-extending for patients with complex psychiatric histories. Here is how to translate the research into clear, effective conversations.

Novo Nordisk Rebrands As 'Novo', Announces Cultural Reset

Sept 14 - Novo Nordisk is changing its day-to-day name to 'Novo', and taking a ⁠new approach to company culture as it looks to claw back ground ⁠in the fierce obesity...

Lilly Says Foundayo Has Captured Over 30% Of New US patients on Oral Weight-loss Drugs

Eli Lilly on Monday said it has captured more than 30% of new patients in the U.S. market for ⁠oral obesity treatments, narrowing the early lead gained by Danish rival Novo...

Experts Urge FDA to Set Clear Safety and Access Standards for Psychedelic Drugs

Doctors, veterans, pharmacists and therapists on Monday urged the U.S. Food and Drug Administration to establish clear safety and access standards for psychedelic therapies...

Todays Updates

First-Line Combo Therapies Best Chemo Alone in NSCLC Trials

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

3D Mammography Improves Long-Term Cancer Risk Prediction

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Todays Updates

First-Line Combo Therapies Best Chemo Alone in NSCLC Trials

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

3D Mammography Improves Long-Term Cancer Risk Prediction

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Latest News

In adults with cystic fibrosis–related diabetes, insulin given after meals provides glucose control similar to that with standard mealtime dosing, offering a flexible treatment option.

Physical inactivity is the single strongest predictor of obesity across US counties, according to a new AI-driven analysis explaining 78% of the variation in county-level obesity prevalence.

New evidence shows GLP-1s are safe and potentially life-extending for patients with complex psychiatric histories. Here is how to translate the research into clear, effective conversations.

Sept 14 - Novo Nordisk is changing its day-to-day name to 'Novo', and taking a ⁠new approach to company culture as it looks to claw back ground ⁠in the fierce obesity...

Eli Lilly on Monday said it has captured more than 30% of new patients in the U.S. market for ⁠oral obesity treatments, narrowing the early lead gained by Danish rival Novo...

Doctors, veterans, pharmacists and therapists on Monday urged the U.S. Food and Drug Administration to establish clear safety and access standards for psychedelic therapies...

News All Time

Novo Nordisk Says Wegovy Approved in China for MASH

Denmark's Novo Nordisk ⁠said on Thursday its blockbuster ⁠weight-loss drug Wegovy had ⁠been approved ‌in China as the first GLP-1 RA class of drugs for the ‌treatment of MASH.

Obesity Rises Faster in Young Adults, Steeper in Older Adults

Obesity is increasing faster among young adults worldwide, even as older adults still carry the greater overall burden, a new analysis of 196 countries over three decades finds.

Diabetes Care in Danish Care Homes May Miss the Mark

About 1 in 8 Danish care home residents with T2D admitted from 2018 to 2023 used glucose-lowering drugs, and most continued treatment despite having A1c levels below recommended targets.

High Semaglutide Dropout Rates Signal Adherence Challenge

With nearly half of patients discontinuing semaglutide within 12 months — especially younger adults — clinicians face a growing challenge in sustaining long-term treatment.

Menopausal Symptoms Worse in Women With Type 2 Diabetes

An observational study finds a higher number of symptoms and greater severity among midlife women with type 2 diabetes than among those without.

Weekly Basal Insulin + Semaglutide Combo May Benefit T2D

Novo Nordisk’s phase 3b trial shows once-weekly IcoSema improves glycemic control and weight with less hypoglycemia than insulin glargine U100 in adults with type 2 diabetes.

Soccer-Spanish FA Launches Fertility Support Programme for Female Players and Referees

Spain's football federation has unveiled an agreement to support fertility treatment for female players and referees, presenting the measure as another way to give women in...

Ultrasound May Help Predict Graves Orbitopathy Risk

Researchers test a new risk score using ultrasound to screen for orbitopathy, a complication estimated to occur in more than 25% of people with Graves disease.

RET Fusion Linked to Occult Lymph Node Metastasis in PTC

A machine learning model uses independent risk factors to identify occult lymph node metastasis in clinically lymph node negative papillary thyroid cancer.

Midwifery Goes Beyond Birth: What Is Still Overlooked?

Midwives’ roles extend across reproductive, pregnancy, postpartum, pelvic floor, and community care, but cultural, structural, and professional barriers can limit their practice.

Tirzepatide Beats Semaglutide for Weight Loss, Not Safety

Tirzepatide may provide greater weight loss than semaglutide in adults with overweight or obesity, but this advantage comes at the cost of a higher risk for serious adverse events.

More Children Under 12 in US Are Being Prescribed Weight-loss Drugs, Study Finds

Prescriptions for GLP-1 weight-loss drugs among children under 12 in the U.S. have risen more than 300-fold since 2019 as doctors ⁠seek new, effective treatments for younger...

Novo Scraps Two More Heart Drug Trials, Further Dimming Growth Beyond Obesity

Novo Nordisk said on Monday it had halted two ⁠additional trials of its experimental cardiovascular drug ziltivekimab, further denting the Danish drugmaker's ⁠efforts to...

MicroRNA Panel May Predict Early Liver Metastasis in PDAC

A machine learning model using 7 exosomal microRNAs can identify patients with pancreatic ductal adenocarcinoma at risk for early liver metastasis.

Can a Smoothie Boost GLP-1 Naturally?

Certain foods and products can support individuals taking GLP-1s for weight management, but they can’t boost GLP-1 production or be used rather than medications.

Metyrapone Linked to Improved Quality of Life in Cushing

Metyrapone is associated with progressive improvements in quality of life among patients with Cushing syndrome, with recovery timing and patterns varying across symptom domains.

Recommended News For You

Lung nodules seen in a high percentage of non-smokers

SBRT May Beat Brachytherapy in Prostate Cancer

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

Rural-urban disparities seen in cervical cancer

Olaparib-Abiraterone in mCRPCs Selected by Biomarkers Outperforms Each Agent by Itself.

The pandemic had little impact on mental health symptoms.

Will a Mindfulness-Based Treatment for Depression Increase Recovery Rates?

Recommended Articles For You

Frontiers in Cancer Therapeutics: U.S. Oncology Trials and Drug Discovery Trends 

Decoding the Failures in Acute Myeloid Leukemia Treatment: Mechanisms, Pathways, & Survival Outcomes 

Digital Oral-Cancer Survivorship Care: Integrating Technology for Enhanced Outcomes 

Understanding Cold Agglutinin Disease: Symptoms, Diagnosis, and Treatment Options  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Which women need more than mammograms for breast cancer screening?

2.

Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?

3.

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.

4.

Genetics and therapy type determine second cancer risk after childhood treatment, study finds

5.

Elder Abuse: Red Flags to Look Out For While Receiving Care.

1.

Unlocking the Mysteries of Rhabdomyoma: A New Hope for Treatment

2.

Neuroendocrine Tumors: Case Study on Diagnosis, Treatment Strategies & Patient Management

3.

Essential Concepts in Oncology for Better Care

4.

Contemporary Trends in Oncology and Patient Outcomes

5.

Optimizing Oncology Practice Revenue: Billing Software, Payer Trends, and Financial Navigation Tools

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases

2.

Navigating the Complexities of Ph Negative ALL - Part XV

3.

Sickle Cell Disease Explained

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot